Triple platelet inhibition in intracranial thrombectomy with additional acute cervical stent angioplasty due to tandem lesion: a retrospective single-center analysis.

Khanafer, Ali; Henkes, Hans; Bücke, Philipp; Hennersdorf, Florian; Bäzner, Hansjörg; Forsting, Michael; von Gottberg, Philipp (2024). Triple platelet inhibition in intracranial thrombectomy with additional acute cervical stent angioplasty due to tandem lesion: a retrospective single-center analysis. BMC neurology, 24(1), p. 99. BioMed Central 10.1186/s12883-024-03597-0

[img]
Preview
Text
s12883-024-03597-0.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

BACKGROUND

Acute stroke treatment with intracranial thrombectomy and treatment of ipsilateral carotid artery stenosis/occlusion ("tandem lesion", TL) in one session is considered safe. However, the risk of stent restenosis after TL treatment is high, and antiplatelet therapy (APT) preventing restenosis must be well balanced to avoid intracranial hemorrhage. We investigated the safety and 90-day outcome of patients receiving TL treatment under triple-APT, focused on stent-patency and possible disadvantageous comorbidities.

METHODS

Patients receiving TL treatment in the setting of acute stroke between 2013 and 2022 were analyzed regarding peri-/postprocedural safety and stent patency after 90 days. All patients received intravenous eptifibatide and acetylsalicylic acid and one of the three drugs prasugrel, clopidogrel, or ticagrelor. Duplex imaging was performed 24 h after treatment, at discharge and 90 days, and digital subtraction angiography was performed if restenosis was suspected.

RESULTS

176 patients were included. Periprocedural complications occurred in 2.3% of the patients at no periprocedural death, and in-hospital death in 13.6%. Discharge mRS score was maintained or improved at the 90-day follow-up in 86%, 4.54% had an in-stent restenosis requiring treatment at 90 days. No recorded comorbidity considered disadvantageous for stent patency showed statistical significance, the duration of the endovascular procedure had no significant effect on outcome.

CONCLUSION

In our data, TL treatment with triple APT resulted in a low restenosis rate, low rates of sICH and a comparably high number of patients with favorable outcome. Aggressive APT in the initial phase may therefore have the potential to prevent recurrent stroke better than restrained platelet inhibition. Comorbidities did not influence stent patency.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Bücke, Philipp Jonas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1471-2377

Publisher:

BioMed Central

Language:

English

Submitter:

Pubmed Import

Date Deposited:

22 Mar 2024 11:57

Last Modified:

22 Mar 2024 12:06

Publisher DOI:

10.1186/s12883-024-03597-0

PubMed ID:

38500074

Uncontrolled Keywords:

Anti-platelet therapy Carotid artery stenting Endovascular thrombectomy In-Stent restenosis Stroke

BORIS DOI:

10.48350/194521

URI:

https://boris.unibe.ch/id/eprint/194521

Actions (login required)

Edit item Edit item
Provide Feedback